These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

591 related items for PubMed ID: 28884320

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.
    Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB.
    Gastroenterology; 2017 Oct; 153(4):996-1005.e1. PubMed ID: 28642197
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effect of sustained virological response to interferon therapy for hepatitis C to the hepatectomy for primary hepatocellular carcinoma.
    Tsujita E, Maeda T, Kayashima H, Harada N, Tsutsui S, Matsuda H, Kinjo N, Ikeda Y, Morita M, Ishida T.
    Hepatogastroenterology; 2015 Oct; 62(137):157-63. PubMed ID: 25911888
    [Abstract] [Full Text] [Related]

  • 11. Second hepatectomy for recurrent hepatocellular carcinoma achieved sustained virological response to interferon therapy for hepatitis C.
    Tsujita E, Yamashita Y, Takeishi K, Maeda T, Takaki S, Mori N, Aisaka Y, Furukawa Y, Shirabe K, Ishida T, Maehara Y.
    Hepatogastroenterology; 2013 Oct; 60(128):2048-54. PubMed ID: 24088310
    [Abstract] [Full Text] [Related]

  • 12. Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma.
    Lee S, Rhim H, Kim YS, Kang TW, Song KD.
    Liver Int; 2016 Apr; 36(4):580-7. PubMed ID: 26503910
    [Abstract] [Full Text] [Related]

  • 13. Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma.
    Song MJ, Bae SH, Lee JS, Lee SW, Song DS, You CR, Choi JY, Yoon SK.
    Korean J Intern Med; 2016 Mar; 31(2):242-52. PubMed ID: 26874512
    [Abstract] [Full Text] [Related]

  • 14. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy.
    Nagaoki Y, Imamura M, Nishida Y, Daijo K, Teraoka Y, Honda F, Nakamura Y, Morio K, Fujino H, Nakahara T, Kawaoka T, Tsuge M, Hiramatsu A, Kawakami Y, Miki D, Hiyama Y, Ochi H, Chayama K, Aikata H.
    J Med Virol; 2019 Apr; 91(4):650-658. PubMed ID: 30381831
    [Abstract] [Full Text] [Related]

  • 15. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma.
    Singal AG, Rich NE, Mehta N, Branch AD, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Ioannou GN, Huang A, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Kagan S, Gopal P, Wong R, Parikh ND, Murphy CC.
    Gastroenterology; 2019 Nov; 157(5):1253-1263.e2. PubMed ID: 31374215
    [Abstract] [Full Text] [Related]

  • 16. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
    Bruno S, Di Marco V, Iavarone M, Roffi L, Boccaccio V, Crosignani A, Cabibbo G, Rossi S, Calvaruso V, Aghemo A, Giacomelli L, Craxì A, Colombo M, Maisonneuve P.
    Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of radiofrequency ablation compared with transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma: a comparative survival analysis.
    Koh PS, Chan AC, Cheung TT, Chok KS, Dai WC, Poon RT, Lo CM.
    HPB (Oxford); 2016 Jan; 18(1):72-8. PubMed ID: 26776854
    [Abstract] [Full Text] [Related]

  • 18. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
    Cabibbo G, Celsa C, Calvaruso V, Petta S, Cacciola I, Cannavò MR, Madonia S, Rossi M, Magro B, Rini F, Distefano M, Larocca L, Prestileo T, Malizia G, Bertino G, Benanti F, Licata A, Scalisi I, Mazzola G, Di Rosolini MA, Alaimo G, Averna A, Cartabellotta F, Alessi N, Guastella S, Russello M, Scifo G, Squadrito G, Raimondo G, Trevisani F, Craxì A, Di Marco V, Cammà C, Rete Sicilia Selezione Terapia – HCV (RESIST-HCV) and Italian Liver Cancer (ITA.LI.CA.) Group.
    J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
    [Abstract] [Full Text] [Related]

  • 19. Comparison of prognosis by viral etiology in patients with hepatocellular carcinoma after radiofrequency ablation.
    Chen PH, Kao WY, Chiou YY, Hung HH, Su CW, Chou YH, Huo TI, Huang YH, Wu WC, Chao Y, Lin HC, Wu JC.
    Ann Hepatol; 2013 Aug; 12(2):263-73. PubMed ID: 23396738
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.